JPMorgan Chase & Co. Has $9.67 Million Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

JPMorgan Chase & Co. reduced its stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 29.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,306,826 shares of the biotechnology company's stock after selling 536,106 shares during the period. JPMorgan Chase & Co. owned 0.43% of Iovance Biotherapeutics worth $9,671,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of IOVA. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of Iovance Biotherapeutics by 16.4% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 29,684 shares of the biotechnology company's stock worth $227,000 after purchasing an additional 4,192 shares during the period. Prudential Financial Inc. boosted its position in shares of Iovance Biotherapeutics by 83.8% during the 4th quarter. Prudential Financial Inc. now owns 31,700 shares of the biotechnology company's stock worth $235,000 after acquiring an additional 14,452 shares in the last quarter. Vanguard Group Inc. increased its stake in Iovance Biotherapeutics by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 27,534,340 shares of the biotechnology company's stock valued at $203,754,000 after acquiring an additional 220,373 shares during the last quarter. LPL Financial LLC raised its position in Iovance Biotherapeutics by 2.6% during the fourth quarter. LPL Financial LLC now owns 250,707 shares of the biotechnology company's stock valued at $1,855,000 after purchasing an additional 6,252 shares in the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in Iovance Biotherapeutics during the fourth quarter worth $301,000. 77.03% of the stock is owned by institutional investors.

Iovance Biotherapeutics Price Performance

NASDAQ IOVA traded down $0.02 on Friday, reaching $3.06. The company had a trading volume of 9,645,501 shares, compared to its average volume of 7,451,823. The firm has a market cap of $1.00 billion, a price-to-earnings ratio of -2.05 and a beta of 1.05. Iovance Biotherapeutics, Inc. has a fifty-two week low of $2.70 and a fifty-two week high of $14.23. The business has a 50 day moving average of $4.00 and a two-hundred day moving average of $6.85.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last released its earnings results on Thursday, February 27th. The biotechnology company reported ($0.26) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.26). The business had revenue of $73.69 million during the quarter, compared to the consensus estimate of $72.17 million. Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%. As a group, research analysts predict that Iovance Biotherapeutics, Inc. will post -1.24 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on IOVA shares. The Goldman Sachs Group lowered their price target on Iovance Biotherapeutics from $18.00 to $16.00 and set a "buy" rating for the company in a report on Thursday. Chardan Capital dropped their target price on shares of Iovance Biotherapeutics from $34.00 to $30.00 and set a "buy" rating for the company in a report on Monday, March 3rd. HC Wainwright reaffirmed a "buy" rating and set a $32.00 price target on shares of Iovance Biotherapeutics in a report on Friday, February 28th. Robert W. Baird dropped their price objective on shares of Iovance Biotherapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a research note on Friday, February 28th. Finally, Barclays decreased their target price on shares of Iovance Biotherapeutics from $22.00 to $5.00 and set an "overweight" rating on the stock in a research note on Monday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $18.22.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.